Galapagos augustus 2020

9.775 Posts, Pagina: « 1 2 3 4 5 6 ... 97 98 99 100 101 102 103 104 105 106 107 ... 485 486 487 488 489 » | Laatste
Pl44
3
quote:

objectief schreef op 8 augustus 2020 15:59:


[...]

Dan wordt het zeker een l.t. belegging, want de 200 wordt al een hele opgave in de rest van dit jaar en 2021. Maar optimisme kan geen kwaad als je in de aandelen belegd, opties dat wordt een ramp.


Objectief gezien weet jij niet beter, dus dan is een domme post oke.

de tuinman
4
quote:

durobinet schreef op 8 augustus 2020 17:31:


Al geplaatst?




Dat is geen goede zin.

Is dit artikel al geplaatst?
Bosebox
0
En AstraZeneca nu aan zet in IPF, mogelijk toekomstige concurrent voor Gilead & Galapagos:

pulmonaryfibrosisnews.com/2020/08/07/...

AstraZeneca Licenses Potential IPF Treatment RXC006 from Redx for Clinical Development

AstraZeneca has acquired a global license for RXC006, an investigational porcupine inhibitor for treating fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), providing $17 million in initial funding to the therapy’s developer Redx Pharma.

AstraZeneca plans to advance RXC006 to a Phase 1 clinical study.

The agreement includes a further $360 million in funding, should RXC006 meet additional development, regulatory, and commercial milestones during the process.

RXC006 is a small molecule designed to block the activity of porcupine, a key enzyme required for the activation of the Wnt signaling pathway, which is a mechanism that regulates cellular growth and development in many types of tissues.

Recent evidence has shown that Wnt activity is central to the scarring (fibrotic) activity observed in patients with IPF.

As the Wnt pathway has known roles in inflammation, cell death, epithelial-mesenchymal transition (a key step in fibrosis development), and fibroblast activation, the blocking of porcupine and Wnt activity by RXC006 is a new approach to limit these events in IPF.

Preclinical studies conducted by Redx showed positive results, demonstrating low levels of Wnt signaling activity in lab-grown lung cells, and, importantly, a reduction of lung scarring in fibrotic mice upon treatment with RXC006.

“We are excited by the potential of porcupine inhibition as a novel approach to tackling fibrotic-associated diseases where there is a real patient need,” Lisa Anson, CEO of Redx, said in a press release.

“This agreement, where AstraZeneca will license this first in class porcupine inhibitor for IPF and progress it into development, highlights, once again, Redx’s ability to generate molecules that have significant potential as novel medicines,” Anson added.

By acquiring the licensing rights to RXC006, AstraZeneca aims to bring the treatment to a clinical trial stage, with the overarching goal of providing a new treatment for IPF patients in need.

“Fibrotic diseases such as idiopathic pulmonary fibrosis have significant impact on patients’ lives and new therapies are urgently needed,” said Mene Pangalos, executive vice president of biopharmaceuticals R&D at AstraZeneca. “We look forward to progressing this porcupine inhibitor into clinical trials as a novel approach to suppress Wnt signalling and potentially modify fibrotic disease processes.”

In addition to work on RXC006, Redx also is actively developing two other small molecule treatments: RXC004, a porcupine inhibitor designed to treat tumors with abnormal Wnt activity, and RXC007, an inhibitor of the protein ROCK2 (Rho Associated Coiled-Coil Containing Protein Kinase 2) designed for treating fibrosis.

RXC004 is being studied in a Phase 1/2 clinical trial (NCT03447470, and still recruiting participants in the U.K.), which is investigating the safety and tolerability of RXC004 in patients with advanced malignancies to determine proper dosage in future studies.

RXC007 is in preclinical development, with studies showing that ROCK2 inhibition reduces fibrosis and lowers pro-fibrotic and pro-inflammatory gene expression in in vivo studies. Redx expects to launch clinical testing of RXC007 in 2021.



durobinet
2
quote:

de tuinman schreef op 8 augustus 2020 17:45:


[...]

Dat is geen goede zin.

Is dit artikel al geplaatst?


Kul! Wel eens van telegramstijl gehoord?
Niet? Lees dit dan: nl.wikipedia.org/wiki/Telegramstijl
BLOO7
0
quote:

de tuinman schreef op 8 augustus 2020 17:45:


[...]

Dat is geen goede zin.

Is dit artikel al geplaatst?


:-) ftw
KR8patser
1
quote:

objectief schreef op 8 augustus 2020 15:59:


[...]

Dan wordt het zeker een l.t. belegging, want de 200 wordt al een hele opgave in de rest van dit jaar en 2021. Maar optimisme kan geen kwaad als je in de aandelen belegd, opties dat wordt een ramp.


Handig zo iemand die in de toekomst kan kijken.

Kunt u mij ook de koers eind 2020 van ING, ASML, FlowTraders en PostNL vertellen?
Dan weet ik of ik goed zit
Beurskingpin
0
quote:

Bosebox schreef op 8 augustus 2020 18:01:


En AstraZeneca nu aan zet in IPF, mogelijk toekomstige concurrent voor Gilead & Galapagos:

pulmonaryfibrosisnews.com/2020/08/07/...

AstraZeneca Licenses Potential IPF Treatment RXC006 from Redx for Clinical Development

AstraZeneca has acquired a global license for RXC006, an investigational porcupine inhibitor for treating fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), providing $17 million in initial funding to the therapy’s developer Redx Pharma.

AstraZeneca plans to advance RXC006 to a Phase 1 clinical study.

The agreement includes a further $360 million in funding, should RXC006 meet additional development, regulatory, and commercial milestones during the process.

RXC006 is a small molecule designed to block the activity of porcupine, a key enzyme required for the activation of the Wnt signaling pathway, which is a mechanism that regulates cellular growth and development in many types of tissues.

Recent evidence has shown that Wnt activity is central to the scarring (fibrotic) activity observed in patients with IPF.

As the Wnt pathway has known roles in inflammation, cell death, epithelial-mesenchymal transition (a key step in fibrosis development), and fibroblast activation, the blocking of porcupine and Wnt activity by RXC006 is a new approach to limit these events in IPF.

Preclinical studies conducted by Redx showed positive results, demonstrating low levels of Wnt signaling activity in lab-grown lung cells, and, importantly, a reduction of lung scarring in fibrotic mice upon treatment with RXC006.

“We are excited by the potential of porcupine inhibition as a novel approach to tackling fibrotic-associated diseases where there is a real patient need,” Lisa Anson, CEO of Redx, said in a press release.

“This agreement, where AstraZeneca will license this first in class porcupine inhibitor for IPF and progress it into development, highlights, once again, Redx’s ability to generate molecules that have significant potential as novel medicines,” Anson added.

By acquiring the licensing rights to RXC006, AstraZeneca aims to bring the treatment to a clinical trial stage, with the overarching goal of providing a new treatment for IPF patients in need.

“Fibrotic diseases such as idiopathic pulmonary fibrosis have significant impact on patients’ lives and new therapies are urgently needed,” said Mene Pangalos, executive vice president of biopharmaceuticals R&D at AstraZeneca. “We look forward to progressing this porcupine inhibitor into clinical trials as a novel approach to suppress Wnt signalling and potentially modify fibrotic disease processes.”

In addition to work on RXC006, Redx also is actively developing two other small molecule treatments: RXC004, a porcupine inhibitor designed to treat tumors with abnormal Wnt activity, and RXC007, an inhibitor of the protein ROCK2 (Rho Associated Coiled-Coil Containing Protein Kinase 2) designed for treating fibrosis.

RXC004 is being studied in a Phase 1/2 clinical trial (NCT03447470, and still recruiting participants in the U.K.), which is investigating the safety and tolerability of RXC004 in patients with advanced malignancies to determine proper dosage in future studies.

RXC007 is in preclinical development, with studies showing that ROCK2 inhibition reduces fibrosis and lowers pro-fibrotic and pro-inflammatory gene expression in in vivo studies. Redx expects to launch clinical testing of RXC007 in 2021.






Had zomaar even galapagos kunnen zijn die deze deal beklonk, genoeg geld..
Windmee
0
quote:

KR8patser schreef op 8 augustus 2020 12:09:


[...]

U gaat op de plek van de moderator zitten ??



was dat opmerking relevant? nee! als ik op de plek van moderator gaat zitten dan begin ik eerst met jou bericht te verwijderen.
sorry je vroeg het om, maar laten we leuk houden :)
objectief
0
quote:

KR8patser schreef op 8 augustus 2020 18:37:


[...]

Handig zo iemand die in de toekomst kan kijken.

Kunt u mij ook de koers eind 2020 van ING, ASML, FlowTraders en PostNL vertellen?
Dan weet ik of ik goed zit



Ik geef slechts mijn verwachte koersontwikkeling; waar is die van jou!!!
objectief
0
quote:

Pl44 schreef op 8 augustus 2020 17:38:


[...]

Objectief gezien weet jij niet beter, dus dan is een domme post oke.




Heb je ook een eigen visie of wil je enkel anderen beledigen.
KR8patser
1
quote:

Windmee schreef op 9 augustus 2020 00:13:


[...]

was dat opmerking relevant? nee! als ik op de plek van moderator gaat zitten dan begin ik eerst met jou bericht te verwijderen.
sorry je vroeg het om, maar laten we leuk houden :)


Oefff die spelling.....netjes een W achter Jou, liefst U, ...
En dan die eerste zin...
Man man man
KR8patser
3
quote:

objectief schreef op 9 augustus 2020 07:59:


[...]

Ik geef slechts mijn verwachte koersontwikkeling; waar is die van jou!!!



Die heb ik hier al 20x neergezet!
Wel opletten, die ga ik niet steeds weer verkondigen als er een nieuwkomer is.
Daarnaast zet ik dan duidelijk neer "ik verwacht", en ik zet niet stellig neer dat het gaat gebeuren !!!
Daarnaast vallen 10 andere ook over je stellige posting heen, dus zoek vooral de fout bij jezelf!
objectief
1
quote:

KR8patser schreef op 9 augustus 2020 08:32:


[...]

Die heb ik hier al 20x neergezet!
Wel opletten, die ga ik niet steeds weer verkondigen als er een nieuwkomer is.
Daarnaast zet ik dan duidelijk neer "ik verwacht", en ik zet niet stellig neer dat het gaat gebeuren !!!
Daarnaast vallen 10 andere ook over je stellige posting heen, dus zoek vooral de fout bij jezelf!



Een visie die niet booming is voor de koers van Gala wordt nooit met blijdschap ontvangen; maar daarom is deze juist veel belangrijker na het naapen van anderen.
NB. ik ga niet elke post hier lezen, er is nog iets anders buiten Gala.
Shortgala
3
quote:

objectief schreef op 9 augustus 2020 08:56:


[...]

NB. ik ga niet elke post hier lezen, er is nog iets anders buiten Gala.


Objectief heeft een ongelooflijk druk en bewogen leven. Het is niks voor objectief om de hele dag naar beurskoersen te kijken, laat staan om de hele dag op een forum rond te struinen! Omwille van de tijd "scant" objectief dan ook het forum en leest slechts enkele, vanzelfsprekend louter de interessante en inhoudelijke, posts...
harvester
0
quote:

Beurskingpin schreef op 8 augustus 2020 19:46:


[...]

Had zomaar even galapagos kunnen zijn die deze deal beklonk, genoeg geld..


Misschien niet interessant genoeg of te duur.
Astra Zeneca heeft en nog meer geld en te weinig in de pijplijn.
Windmee
1
quote:

KR8patser schreef op 9 augustus 2020 08:29:


[...]

Oefff die spelling.....netjes een W achter Jou, liefst U, ...
En dan die eerste zin...
Man man man

Mijn laatste antwoord naar JIJ, JIJ fervuil did vorum, STOP ermee, zo moe van JIJ
Actie is altijd reactie!
bws
1
quote:

Bosebox schreef op 8 augustus 2020 18:01:


En AstraZeneca nu aan zet in IPF, mogelijk toekomstige concurrent voor Gilead & Galapagos:

pulmonaryfibrosisnews.com/2020/08/07/...

AstraZeneca Licenses Potential IPF Treatment RXC006 from Redx for Clinical Development

AstraZeneca has acquired a global license for RXC006, an investigational porcupine inhibitor for treating fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), providing $17 million in initial funding to the therapy’s developer Redx Pharma.

AstraZeneca plans to advance RXC006 to a Phase 1 clinical study.

The agreement includes a further $360 million in funding, should RXC006 meet additional development, regulatory, and commercial milestones during the process.

RXC006 is a small molecule designed to block the activity of porcupine, a key enzyme required for the activation of the Wnt signaling pathway, which is a mechanism that regulates cellular growth and development in many types of tissues.

Recent evidence has shown that Wnt activity is central to the scarring (fibrotic) activity observed in patients with IPF.

As the Wnt pathway has known roles in inflammation, cell death, epithelial-mesenchymal transition (a key step in fibrosis development), and fibroblast activation, the blocking of porcupine and Wnt activity by RXC006 is a new approach to limit these events in IPF.

Preclinical studies conducted by Redx showed positive results, demonstrating low levels of Wnt signaling activity in lab-grown lung cells, and, importantly, a reduction of lung scarring in fibrotic mice upon treatment with RXC006.

“We are excited by the potential of porcupine inhibition as a novel approach to tackling fibrotic-associated diseases where there is a real patient need,” Lisa Anson, CEO of Redx, said in a press release.

“This agreement, where AstraZeneca will license this first in class porcupine inhibitor for IPF and progress it into development, highlights, once again, Redx’s ability to generate molecules that have significant potential as novel medicines,” Anson added.

By acquiring the licensing rights to RXC006, AstraZeneca aims to bring the treatment to a clinical trial stage, with the overarching goal of providing a new treatment for IPF patients in need.

“Fibrotic diseases such as idiopathic pulmonary fibrosis have significant impact on patients’ lives and new therapies are urgently needed,” said Mene Pangalos, executive vice president of biopharmaceuticals R&D at AstraZeneca. “We look forward to progressing this porcupine inhibitor into clinical trials as a novel approach to suppress Wnt signalling and potentially modify fibrotic disease processes.”

In addition to work on RXC006, Redx also is actively developing two other small molecule treatments: RXC004, a porcupine inhibitor designed to treat tumors with abnormal Wnt activity, and RXC007, an inhibitor of the protein ROCK2 (Rho Associated Coiled-Coil Containing Protein Kinase 2) designed for treating fibrosis.

RXC004 is being studied in a Phase 1/2 clinical trial (NCT03447470, and still recruiting participants in the U.K.), which is investigating the safety and tolerability of RXC004 in patients with advanced malignancies to determine proper dosage in future studies.

RXC007 is in preclinical development, with studies showing that ROCK2 inhibition reduces fibrosis and lowers pro-fibrotic and pro-inflammatory gene expression in in vivo studies. Redx expects to launch clinical testing of RXC007 in 2021.






En nu op naar fase 1 onderzoek. T/M fase 2 sneuvelen nogal wat projecten.Het schijnt dat er concurrentie is die wat verder is....
Windmee
2
quote:

KR8patser schreef op 9 augustus 2020 08:32:


[...]

Die heb ik hier al 20x neergezet!
Wel opletten, die ga ik niet steeds weer verkondigen als er een nieuwkomer is.
Daarnaast zet ik dan duidelijk neer "ik verwacht", en ik zet niet stellig neer dat het gaat gebeuren !!!
Daarnaast vallen 10 andere ook over je stellige posting heen, dus zoek vooral de fout bij jezelf!



[ga ik niet steeds weer verkondigen als er een nieuwkomer is]

whahahahah, zelf pas nog op 28 juli 2020 lid, whahahahah er zijn hier al leden die al lid zijn toen JIJ nog een luier droeg, je bent wel erg brutaal.
9.775 Posts, Pagina: « 1 2 3 4 5 6 ... 97 98 99 100 101 102 103 104 105 106 107 ... 485 486 487 488 489 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 24 nov 2020 17:35
Koers 104,800
Verschil -0,300 (-0,29%)
Hoog 105,950
Laag 103,600
Volume 429.779
Volume gemiddeld 466.385
Volume gisteren 313.582